An observational study in Bariatric Surgery Candidate, Cardiovascular Diseases and Type 2 Diabetes, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Vanderbilt University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hypertension by Vanderbilt University Medical Center — 8 open to participants now, 8 under way, none of them phase 3. Hypertension · Vanderbilt University Medical Center.
Among the 23 studies in Hypertension by Vanderbilt University Medical Center, this one is one of 4 that started in 2021, is one of 4 observational ones, and was the 15th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →8 of the 23 studies in Hypertension by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Women only
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Vanderbilt University Medical Center · Sites in United States
Ages 40–80
Vanderbilt University Medical Center · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 4 2
First in 2008; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is below the median of 352 across 1,166 observational studies indexed under Hypertension.
Median enrollment 20 across the 19 interventional studies, 400 across the 4 observational. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
3 of the studies in Hypertension by Vanderbilt University Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03042988Vanderbilt University Medical CenterOvernight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension | 2026-11-30 |
| NCT03312556Vanderbilt University Medical CenterTreatment of Supine Hypertension in Autonomic Failure (CPAP) | 2026-12-21 |
| NCT05489575Vanderbilt University Medical CenterCPAP for the Treatment of Supine Hypertension | 2027-03-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Hypertension by Vanderbilt University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metabolic surgery is an emerging option to treat obesity-related metabolic diseases (e.g., type 2 diabetes) and prevent cardiovascular disease (CVD). Metabolic surgery can profoundly alter the gut microbiota; meanwhile, gut microbiota may affect surgical outcomes. Longitudinal studies that examined pre- to post-surgery changes in gut microbiota and its relation to cardiometabolic health after surgery are limited. Furthermore, few studies have included African Americans, a population with high rates of cardiometabolic diseases. The investigators aim to fill these research gaps by establishing a longitudinal, observational study of metabolic surgery patients and applying multi-omics to identify stool, blood, and/or tissue microbial features related to post-surgery cardiometabolic outcomes. In the current study, the investigators plan to enroll up to 300 patients who undergo metabolic surgery at Vanderbilt University Medical Center and follow them for up to 10 years after surgery. Fasting blood and stool samples will be collected at pre-surgery and 3-month, 1-year, 2-year, and 3-year post-surgery clinical visits. Tissue samples (e.g., biopsies of the liver and adipose and remnants of the stomach) will be collected during operation. Meanwhile, participants will complete a REDCap survey at baseline and 1-year, 2-year, and 3-year post-surgery. Participants' electronic medical records will be used to obtain additional information and facilitate long-term follow-up. The investigators will evaluate pre- to post-surgery changes in the fecal microbiome and fecal and blood levels of metabolites and proteins and the associations of microbiome, metabolites, and proteins with cardiometabolic improvements after surgery. This study will advance our understanding of the role of gut microbiota in metabolic surgery, which may translate into novel approaches to identify and treat obese patients for better cardiometabolic health.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
This study's planned enrollment of 300 is below the median of 352 across 1,166 observational studies indexed under Hypertension.
Browse Hypertension studies →Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
Compared within Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
We plan to enroll 300 patients who undergo metabolic surgery at the Vanderbilt University Medical Center and follow them up to 10 years after surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)
Estimated 10-year risk of atherosclerotic cardiovascular disease
The 10-year risk of atherosclerotic cardiovascular disease based on the American College of Cardiology/American Heart Association pooled cohort equations, incorporating age, sex, race, systolic blood pressure, total cholesterol, HDL cholesterol, diabetes status, hypertension status, and smoking
Time frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
Glycated hemoglobin
Time frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
Blood pressure
Time frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
Blood cholesterol
Total, low-density, and high-density lipoprotein cholesterol
Time frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
Blood inflammatory proteins
high-sensitivity C-reactive protein
Time frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started Aug 2021 (actual). Primary completion is estimated for Dec 2028, 88 months after the start.
Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 88 months is above that.
Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →